1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Wilms’ Tumor (Nephroblastoma) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Wilms’ Tumor (Nephroblastoma)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Wilms’ Tumor (Nephroblastoma).
- A review of the marketed products under prescription for Wilms’ Tumor (Nephroblastoma), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Wilms’ Tumor (Nephroblastoma) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Wilms’ Tumor (Nephroblastoma) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Wilms’ Tumor (Nephroblastoma) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Wilms’ Tumor (Nephroblastoma) drugs.
- Coverage of Wilms’ Tumor (Nephroblastoma) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Wilms’ Tumor (Nephroblastoma) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Wilms’ Tumor (Nephroblastoma).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Wilms’ Tumor (Nephroblastoma).
- API intelligence over marketed drugs for Wilms’ Tumor (Nephroblastoma) and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Wilms’ Tumor (Nephroblastoma).
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Wilms’ Tumor (Nephroblastoma) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Wilms' Tumor (Nephroblastoma) Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Wilms' Tumor (Nephroblastoma) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Wilms' Tumor (Nephroblastoma) Therapeutic Market, US, (Year), 2014
Wilms' Tumor (Nephroblastoma) Marketed Drugs, API Manufacturers by US DMF Status, 2014
Wilms' Tumor (Nephroblastoma) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Wilms' Tumor (Nephroblastoma) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Wilms' Tumor (Nephroblastoma) Therapeutic Market, Global Sales (in million USD), 2014
Wilms' Tumor (Nephroblastoma) Marketed Drugs, API Manufacturers, Global, 2014
Wilms' Tumor (Nephroblastoma) Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Wilms' Tumor (Nephroblastoma), 2014?


List of Figures

Wilms' Tumor (Nephroblastoma) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Wilms' Tumor (Nephroblastoma) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Wilms' Tumor (Nephroblastoma) Therapeutic Market, US, (Year), 2014
Wilms' Tumor (Nephroblastoma) Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Wilms' Tumor (Nephroblastoma) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Wilms' Tumor (Nephroblastoma) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Wilms' Tumor (Nephroblastoma) Therapeutic Market, Global Sales (in million USD), 2014
Wilms' Tumor (Nephroblastoma) Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer and Breast Cancer Statistics in Switzerland

  • February 2017
    138 pages
  • Cancer  

    Breast Cancer  

    Obesity  

  • Switzerland  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Cancer Statistics

5 days ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.